Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26367715 | 0.98 | KMO (0.53) | HDAC4HDAC2HDAC8KMOCYP11B2 | |
| SCHEMBL19671564 | 0.91 | HTR2C (0.42) | HDAC4HDAC2HDAC8KMOHTR2C | |
| SCHEMBL778529 | 0.86 | HDAC4 (0.63) | HDAC4HDAC2HDAC8KMOCYP11B2 | |
| SCHEMBL5667650 | 0.84 | KMO (0.64) | HDAC4HDAC2HDAC8KMOCYP11B2 | |
| SCHEMBL669730 | 0.84 | KMO (0.64) | HDAC4HDAC2HDAC8KMOCYP11B2 | |
| SCHEMBL8044618 | 0.82 | HTR2C (0.62) | HTR2CSLC18A3 | |
| SCHEMBL7294404 | 0.82 | HTR2C (0.37) | HDAC4HDAC2HDAC8KMOHTR2C | |
| SCHEMBL5666805 | 0.81 | KMO (0.62) | HDAC4HDAC2HDAC8KMOCYP11B2 | |
| Hydrogen Peroxide SCHEMBL11391460 | 0.79 | KMO (0.71) | HDAC4HDAC2HDAC8KMOCYP11B2 | |
| SCHEMBL12825091 | 0.79 | QDPR (0.53) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328285-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
| US-7589095-B2 | 4-phenyl-pyrimidine-2-carbonitrile derivatives | N.V. ORGANON (NL) | 2009-09-15 | — | — | US | disclosed |
| EP-1758870-B1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | ORGANON NV (NL) | 2008-08-13 | — | — | EP | disclosed |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | Cai, Jiaqiang | 2008-04-17 | — | — | US | disclosed |
| CN-1980897-A | 4-phenyl-pyrimidine-2-carbonitrile derivatives | ORGANON NV (NL) | 2007-06-13 | — | — | CN | disclosed |
| EP-1758870-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. Organon (NL) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121106-A1 | 4-PHENYL-PYRIMIDINE-2-CARBONITRILE DERIVATIVES | N.V. ORGANON (NL) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | HDAC4 1929/4885HDAC2 1343/4885HDAC8 2301/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | HDAC4 1929/4885HDAC2 1343/4885HDAC8 2301/4885 |
| US-20080090813-A1 | 4-Phenyl-Pyrimidine-2-Carbonitrile Derivatives | P2RY4, P2RX4, P2RY1 | HDAC4 2249/4885HDAC2 1864/4885HDAC8 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.